Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization

Vincenzo Ingangi, A. Piontini, Ali Munaim Yousif, Francesco Merlino, Paolo Grieco, Maria Vincenza Carriero

Research output: Contribution to journalArticle

Abstract

Background: Leukocyte migration across the blood barrier and into tissues represents a key process in the pathogenesis of inflammatory bowel diseases. The urokinase receptor (urokinase-type plasminogen activator receptor) is a master regulator of leukocyte recruitment. We recently found that cyclization of the urokinase-type plasminogen activator receptor-derived peptide Ser-Arg-Ser-Arg-Tyr [SRSRY] inhibits transendothelial migration of monocytes. Now, we have explored the effects of [SRSRY] administration during experimental colitis. Methods: The effects of [SRSRY] on cytokine profile, cytoskeletal organization, and cell migration were investigated using phorbol-12-myristate acetate-differentiated THP-1 cells exposed to polarizing stimuli. In vivo, [SRSRY] was intraperitoneally administered during dextran sodium sulfate- or 2,4,6-trinitrobenzene sulfonic acid-induced colitis in wild-type or urokinase-type plasminogen activator receptor knockout mice. Levels of pro-inflammatory cytokines and inflammatory monocytes in mucosal infiltrates were assessed by enzyme-linked immunosorbent assay and flow cytometry, respectively. Results: [SRSRY] prevents M0 to M1 transition and migration of M1 polarized macrophages. In vivo, [SRSRY] reduces intestinal inflammation diminishing body weight loss and disease activity index. These beneficial effects are accompanied by a reduction of interleukin 1β, interleukin 6, and tumor necrosis factor α, an increase of interleukin 10, and an abridged recruitment of inflammatory monocytes to the inflamed tissue. Conclusions: Altogether, these findings indicate that [SRSRY] may be considered as a new drug useful for the pharmacological treatment of chronic inflammatory diseases, such as inflammatory bowel diseases.

Original languageEnglish
Pages (from-to)2390-2401
Number of pages12
JournalInflammatory Bowel Diseases
Volume22
Issue number10
DOIs
Publication statusPublished - Aug 26 2016

Fingerprint

Urokinase Plasminogen Activator Receptors
Urokinase-Type Plasminogen Activator
Colitis
Monocytes
Macrophages
Peptides
Inflammatory Bowel Diseases
Leukocytes
Cytokines
Transendothelial and Transepithelial Migration
Dextran Sulfate
Sulfonic Acids
Tetradecanoylphorbol Acetate
Cyclization
Therapeutics
Interleukin-1
Knockout Mice
Interleukin-10
Cell Movement
Weight Loss

Keywords

  • experimental colitis
  • inflammatory bowel diseases
  • macrophages
  • monocytes
  • peptides
  • urokinase receptor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization. / Ingangi, Vincenzo; Piontini, A.; Yousif, Ali Munaim; Merlino, Francesco; Grieco, Paolo; Carriero, Maria Vincenza.

In: Inflammatory Bowel Diseases, Vol. 22, No. 10, 26.08.2016, p. 2390-2401.

Research output: Contribution to journalArticle

Ingangi, Vincenzo ; Piontini, A. ; Yousif, Ali Munaim ; Merlino, Francesco ; Grieco, Paolo ; Carriero, Maria Vincenza. / Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization. In: Inflammatory Bowel Diseases. 2016 ; Vol. 22, No. 10. pp. 2390-2401.
@article{2f48ea0243fc415992d809a348023a48,
title = "Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization",
abstract = "Background: Leukocyte migration across the blood barrier and into tissues represents a key process in the pathogenesis of inflammatory bowel diseases. The urokinase receptor (urokinase-type plasminogen activator receptor) is a master regulator of leukocyte recruitment. We recently found that cyclization of the urokinase-type plasminogen activator receptor-derived peptide Ser-Arg-Ser-Arg-Tyr [SRSRY] inhibits transendothelial migration of monocytes. Now, we have explored the effects of [SRSRY] administration during experimental colitis. Methods: The effects of [SRSRY] on cytokine profile, cytoskeletal organization, and cell migration were investigated using phorbol-12-myristate acetate-differentiated THP-1 cells exposed to polarizing stimuli. In vivo, [SRSRY] was intraperitoneally administered during dextran sodium sulfate- or 2,4,6-trinitrobenzene sulfonic acid-induced colitis in wild-type or urokinase-type plasminogen activator receptor knockout mice. Levels of pro-inflammatory cytokines and inflammatory monocytes in mucosal infiltrates were assessed by enzyme-linked immunosorbent assay and flow cytometry, respectively. Results: [SRSRY] prevents M0 to M1 transition and migration of M1 polarized macrophages. In vivo, [SRSRY] reduces intestinal inflammation diminishing body weight loss and disease activity index. These beneficial effects are accompanied by a reduction of interleukin 1β, interleukin 6, and tumor necrosis factor α, an increase of interleukin 10, and an abridged recruitment of inflammatory monocytes to the inflamed tissue. Conclusions: Altogether, these findings indicate that [SRSRY] may be considered as a new drug useful for the pharmacological treatment of chronic inflammatory diseases, such as inflammatory bowel diseases.",
keywords = "experimental colitis, inflammatory bowel diseases, macrophages, monocytes, peptides, urokinase receptor",
author = "Vincenzo Ingangi and A. Piontini and Yousif, {Ali Munaim} and Francesco Merlino and Paolo Grieco and Carriero, {Maria Vincenza}",
year = "2016",
month = "8",
day = "26",
doi = "10.1097/MIB.0000000000000896",
language = "English",
volume = "22",
pages = "2390--2401",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage Polarization

AU - Ingangi, Vincenzo

AU - Piontini, A.

AU - Yousif, Ali Munaim

AU - Merlino, Francesco

AU - Grieco, Paolo

AU - Carriero, Maria Vincenza

PY - 2016/8/26

Y1 - 2016/8/26

N2 - Background: Leukocyte migration across the blood barrier and into tissues represents a key process in the pathogenesis of inflammatory bowel diseases. The urokinase receptor (urokinase-type plasminogen activator receptor) is a master regulator of leukocyte recruitment. We recently found that cyclization of the urokinase-type plasminogen activator receptor-derived peptide Ser-Arg-Ser-Arg-Tyr [SRSRY] inhibits transendothelial migration of monocytes. Now, we have explored the effects of [SRSRY] administration during experimental colitis. Methods: The effects of [SRSRY] on cytokine profile, cytoskeletal organization, and cell migration were investigated using phorbol-12-myristate acetate-differentiated THP-1 cells exposed to polarizing stimuli. In vivo, [SRSRY] was intraperitoneally administered during dextran sodium sulfate- or 2,4,6-trinitrobenzene sulfonic acid-induced colitis in wild-type or urokinase-type plasminogen activator receptor knockout mice. Levels of pro-inflammatory cytokines and inflammatory monocytes in mucosal infiltrates were assessed by enzyme-linked immunosorbent assay and flow cytometry, respectively. Results: [SRSRY] prevents M0 to M1 transition and migration of M1 polarized macrophages. In vivo, [SRSRY] reduces intestinal inflammation diminishing body weight loss and disease activity index. These beneficial effects are accompanied by a reduction of interleukin 1β, interleukin 6, and tumor necrosis factor α, an increase of interleukin 10, and an abridged recruitment of inflammatory monocytes to the inflamed tissue. Conclusions: Altogether, these findings indicate that [SRSRY] may be considered as a new drug useful for the pharmacological treatment of chronic inflammatory diseases, such as inflammatory bowel diseases.

AB - Background: Leukocyte migration across the blood barrier and into tissues represents a key process in the pathogenesis of inflammatory bowel diseases. The urokinase receptor (urokinase-type plasminogen activator receptor) is a master regulator of leukocyte recruitment. We recently found that cyclization of the urokinase-type plasminogen activator receptor-derived peptide Ser-Arg-Ser-Arg-Tyr [SRSRY] inhibits transendothelial migration of monocytes. Now, we have explored the effects of [SRSRY] administration during experimental colitis. Methods: The effects of [SRSRY] on cytokine profile, cytoskeletal organization, and cell migration were investigated using phorbol-12-myristate acetate-differentiated THP-1 cells exposed to polarizing stimuli. In vivo, [SRSRY] was intraperitoneally administered during dextran sodium sulfate- or 2,4,6-trinitrobenzene sulfonic acid-induced colitis in wild-type or urokinase-type plasminogen activator receptor knockout mice. Levels of pro-inflammatory cytokines and inflammatory monocytes in mucosal infiltrates were assessed by enzyme-linked immunosorbent assay and flow cytometry, respectively. Results: [SRSRY] prevents M0 to M1 transition and migration of M1 polarized macrophages. In vivo, [SRSRY] reduces intestinal inflammation diminishing body weight loss and disease activity index. These beneficial effects are accompanied by a reduction of interleukin 1β, interleukin 6, and tumor necrosis factor α, an increase of interleukin 10, and an abridged recruitment of inflammatory monocytes to the inflamed tissue. Conclusions: Altogether, these findings indicate that [SRSRY] may be considered as a new drug useful for the pharmacological treatment of chronic inflammatory diseases, such as inflammatory bowel diseases.

KW - experimental colitis

KW - inflammatory bowel diseases

KW - macrophages

KW - monocytes

KW - peptides

KW - urokinase receptor

UR - http://www.scopus.com/inward/record.url?scp=84988642791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988642791&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000000896

DO - 10.1097/MIB.0000000000000896

M3 - Article

VL - 22

SP - 2390

EP - 2401

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 10

ER -